A
Agita Jeruma
Publications - 8
Citations - 580
Agita Jeruma is an academic researcher. The author has contributed to research in topics: Cirrhosis & Disease burden. The author has an hindex of 3, co-authored 8 publications receiving 543 citations.
Papers
More filters
Journal ArticleDOI
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.
A. Sibley,Kwang Hyub Han,A. Abourached,Laurentius A. Lesmana,Mihály Makara,Wasim Jafri,Riina Salupere,Abdullah M. Assiri,Adrian Goldis,Faisal Abaalkhail,Zaigham Abbas,A. Abdou,F. Al Braiki,F. Al Hosani,K. Al Jaberi,M. Al Khatry,M. A. Al Mulla,H. Al Quraishi,A. Al Rifai,Y. Al Serkal,Altaf Alam,Seyed Moayed Alavian,Hamad I. Al-Ashgar,S. Alawadhi,L. Al-Dabal,P. Aldins,Faleh Z. Al-Faleh,Abdullah S. Alghamdi,R. Al-Hakeem,Abdulrahman Aljumah,A. Almessabi,Adel Alqutub,Khalid Alswat,Ibrahim Altraif,M. Alzaabi,N. Andrea,Mohamed A. Babatin,A. Baqir,M. T. Barakat,Ottar M. Bergmann,Abdul Rahman Bizri,Sarah Blach,Asad Chaudhry,M. S. Choi,T. Diab,Samsuridjal Djauzi,E. S. El Hassan,S. El Khoury,Chris Estes,S. Fakhry,J. I. Farooqi,J. I. Farooqi,H. Fridjonsdottir,Rino Alvani Gani,A. Ghafoor Khan,Liana Gheorghe,Magnus Gottfredsson,S. Gregorcic,Jessie Gunter,Behzad Hajarizadeh,Behzad Hajarizadeh,Saeed Hamid,Irsan Hasan,Almoutaz Hashim,Gabor Horvath,Béla Hunyady,R. Husni,Agita Jeruma,Jon G. Jonasson,Jon G. Jonasson,B. Karlsdottir,Do Young Kim,Young Seok Kim,Z. Koutoubi,Valentina Liakina,Valentina Liakina,Young-Suk Lim,A. Löve,A. Löve,Matti Maimets,Reza Malekzadeh,Mojca Maticic,Muhammad S. Memon,Shahin Merat,Jacques E Mokhbat,Fadi H. Mourad,David H. Muljono,David H. Muljono,Arif Nawaz,N. Nugrahini,S. Olafsson,S. Priohutomo,H. Qureshi,P. Rassam,Homie Razavi,Devin Razavi-Shearer,Kathryn Razavi-Shearer,Baiba Rozentale,M. Sadik,K. Saeed,A. Salamat,Faisal M. Sanai,A. Sanityoso Sulaiman,R. A. Sayegh,Ala I. Sharara,M. Siddiq,A. M. Siddiqui,G. Sigmundsdottir,B. Sigurdardottir,Danute Speiciene,Andri Sanityoso Sulaiman,Marwa Sultan,M. Taha,Junko Tanaka,H. Tarifi,G. Tayyab,Ieva Tolmane,M. Ud Din,M. Umar,M. Umar,M. Umar,Jonas Valantinas,J. Videčnik-Zorman,Cesar Yaghi,Evy Yunihastuti,M. A. Yusuf,Bader Faiyaz Zuberi,Jonathan Schmelzer +127 more
TL;DR: The current treatment rate and efficacy are not sufficient to manage the disease burden of hepatitis C virus and alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver‐related deaths from increasing.
Journal ArticleDOI
Strategies to manage hepatitis C virus infection disease burden - Volume 3
Faleh Z. Al-Faleh,N. Nugrahini,Mojca Matičič,Ieva Tolmane,M. Alzaabi,Behzad Hajarizadeh,Behzad Hajarizadeh,Jonas Valantinas,Do Young Kim,Béla Hunyady,Faisal Abaalkhail,Zaigham Abbas,A. Abdou,A. Abourached,F. Al Braiki,F. Al Hosani,K. Al Jaberi,M. Al Khatry,M. A. Al Mulla,H. Al Quraishi,A. Al Rifai,Y. Al Serkal,Altaf Alam,Hamad I. Al-Ashgar,Seyed M Alavian,S. Alawadhi,L. Al-Dabal,P. Aldins,Abdullah S. Alghamdi,R. Al-Hakeem,Abdulrahman Aljumah,A. Almessabi,Adel Alqutub,Khalid Alswat,Ibrahim Altraif,N. Andrea,Abdullah M. Assiri,Mohamed A. Babatin,A. Baqir,M. T. Barakat,Ottar M. Bergmann,Abdul Rahman Bizri,Asad Chaudhry,Moon Suk Choi,T. Diab,Samsuridjal Djauzi,E. S. El Hassan,S. El Khoury,Chris Estes,S. Fakhry,Javed Iqbal Farooqi,Javed Iqbal Farooqi,H. Fridjonsdottir,Rino Alvani Gani,A. Ghafoor Khan,Liana Gheorghe,Adrian Goldis,Magnus Gottfredsson,S. Gregorcic,Jessie Gunter,Saeed Hamid,Kwang Hyub Han,Irsan Hasan,Almoutaz Hashim,Gabor Horvath,R. Husni,Wasim Jafri,Agita Jeruma,Jon G. Jonasson,Jon G. Jonasson,B. Karlsdottir,Young Seok Kim,Z. Koutoubi,Laurentius A. Lesmana,Valentina Liakina,Valentina Liakina,Young-Suk Lim,A. Löve,A. Löve,Matti Maimets,Mihály Makara,Reza Malekzadeh,Muhammad S. Memon,Shahin Merat,Jacques E Mokhbat,Fadi H. Mourad,David H. Muljono,David H. Muljono,Arif Nawaz,S. Olafsson,S. Priohutomo,H. Qureshi,P. Rassam,Homie Razavi,Devin Razavi-Shearer,Kathryn Razavi-Shearer,Baiba Rozentale,M. Sadik,K. Saeed,A. Salamat,Riina Salupere,Faisal M. Sanai,A. Sanityoso Sulaiman,R. A. Sayegh,Jonathan Schmelzer,Ala I. Sharara,A. Sibley,M. Siddiq,A. M. Siddiqui,G. Sigmundsdottir,B. Sigurdardottir,Danute Speiciene,Andri Sanityoso Sulaiman,Marwa Sultan,M. Taha,Junko Tanaka,H. Tarifi,G. Tayyab,M. Ud Din,M. Umar,M. Umar,J. Videčnik-Zorman,Cesar Yaghi,Evy Yunihastuti,M. A. Yusuf,Bader Faiyaz Zuberi,Sarah Blach +126 more
TL;DR: A 90% reduction in total HCV infections within 15 years is feasible in most countries studied, but it required a coordinated effort to introduce harm reduction programmes to reduce new infections, screening to identify those already infected and treatment with high cure rate therapies.
Journal ArticleDOI
Natural clearance of hepatitis C virus in hemophilia patients
Raimonds Simanis,Sandra Lejniece,Arturs Sochnevs,Jelena Eglite,Gunta Chernevska,Zhanna Kovalova,Dace Gardovska,Agita Jeruma,Velga Kuse,Ludmila Viksna +9 more
TL;DR: There is an association between natural clearance of HCV and HLA allele DRB1*07 in hemophilia patients and children are more likely to clear virus naturally than adults.
Journal ArticleDOI
Direct-acting antivirals ombitasvir / paritaprevir / ritonavir + dasabuvir with or without ribavirin in hepatitis C virus (HCV) genotype 1-infected treatment-naive or treatment-experienced patients with or without cirrhosis: Real-life experience in Lithuania and Latvia
Ligita Jancoriene,Katazyna Polubenko,Edita Kazenaite,Arida Buivydiene,Jolita Jakutiene,Ieva Tolmane,Agita Jeruma,Daiva Radzisauskiene,Evelina Mockiene,Arvydas Ambrozaitis +9 more
TL;DR: The current real-life study demonstrated the effectiveness and safety of OBV/PTV/r + DSV ± RBV in patients with HCV GT1, including patients with cirrhosis, a liver transplant recipient and the one who failed previous antiviral therapies.
Journal ArticleDOI
Original Versus Generic Direct Acting Antivirals in Treatment of Chronic Hepatitis C Patients: Real Life Data From Latvia
TL;DR: Study results show high efficacy of both regimens using original and generic medicines - sustained virologic response was achieved in more than 90% of patients, with slight superiority in original medicines group.